Re: Lepore et al.: Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings (Ophthalmology. 2018;125:218-226) REPLY

Domenico Lepore; M. H. Ji; G. Quinn

doi:10.1016/j.ophtha.2018.04.012

Re: Lepore et al.: Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings (Ophthalmology. 2018;125:218-226) REPLY

Domenico Lepore^*
, M. H. Ji
, G. Quinn

^*Autore corrispondente per questo lavoro

University of Pennsylvania

Risultato della ricerca: Contributo in rivista › Articolo

1 Citazioni (Scopus)

Abstract

N/A

Lingua originale	Inglese
pagine (da-a)	e71-e72
Rivista	Ophthalmology
Volume	125
Numero di pubblicazione	10
DOI	https://doi.org/10.1016/j.ophtha.2018.04.012
Stato di pubblicazione	Pubblicato - 2018

All Science Journal Classification (ASJC) codes

Oftalmologia

Keywords

Bevacizumab
Fluoresceins
Follow-Up Studies
Humans
Infant
Intravitreal Injections
Newborn
Retinopathy of Prematurity

Accesso al documento

10.1016/j.ophtha.2018.04.012

Altri file e collegamenti

Fingerprint

Entra nei temi di ricerca di 'Re: Lepore et al.: Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings (Ophthalmology. 2018;125:218-226) REPLY'. Insieme formano una fingerprint unica.

Cita questo

@article{f4019b740d194eacb964f338bfeef19e,

title = "Re: Lepore et al.: Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings (Ophthalmology. 2018;125:218-226) REPLY",

abstract = "N/A",

keywords = "Bevacizumab, Fluoresceins, Follow-Up Studies, Humans, Infant, Intravitreal Injections, Newborn, Retinopathy of Prematurity, Bevacizumab, Fluoresceins, Follow-Up Studies, Humans, Infant, Intravitreal Injections, Newborn, Retinopathy of Prematurity",

author = "Domenico Lepore and Ji, \{M. H.\} and G. Quinn",

year = "2018",

doi = "10.1016/j.ophtha.2018.04.012",

language = "English",

volume = "125",

pages = "e71--e72",

journal = "Ophthalmology",

issn = "0161-6420",

publisher = "Elsevier Inc.",

number = "10",

}

Re: Lepore et al.: Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings (Ophthalmology. 2018;125:218-226) REPLY. / Lepore, Domenico; Ji, M. H.; Quinn, G.
In: Ophthalmology, Vol. 125, N. 10, 2018, pag. e71-e72.

Risultato della ricerca: Contributo in rivista › Articolo

TY - JOUR

T1 - Re: Lepore et al.: Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings (Ophthalmology. 2018;125:218-226) REPLY

AU - Lepore, Domenico

AU - Ji, M. H.

AU - Quinn, G.

PY - 2018

Y1 - 2018

N2 - N/A

AB - N/A

KW - Bevacizumab

KW - Fluoresceins

KW - Follow-Up Studies

KW - Humans

KW - Infant

KW - Intravitreal Injections

KW - Newborn

KW - Retinopathy of Prematurity

KW - Bevacizumab

KW - Fluoresceins

KW - Follow-Up Studies

KW - Humans

KW - Infant

KW - Intravitreal Injections

KW - Newborn

KW - Retinopathy of Prematurity

UR - https://publicatt.unicatt.it/handle/10807/170721

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85053423560&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85053423560&origin=inward

U2 - 10.1016/j.ophtha.2018.04.012

DO - 10.1016/j.ophtha.2018.04.012

M3 - Article

SN - 0161-6420

VL - 125

SP - e71-e72

JO - Ophthalmology

JF - Ophthalmology

IS - 10

ER -